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Abstract
Background: Omentin-1 is a novel adipokine expressed in visceral adipose tissue and negatively associated with
insulin resistance and obesity. We aimed to study the effects of weight loss-induced improved insulin sensitivity on
circulating omentin concentrations.
Methods: Circulating omentin-1 (ELISA) concentration in association with metabolic variables was measured in
35 obese subjects (18 men, 17 women) before and after hypocaloric weight loss.
Results: Baseline circulating omentin-1 concentrations correlated negatively with BMI (r = -0.58, p < 0.001), body
weight (r = -0.35, p = 0.045), fat mass (r = -0.67, p < 0.001), circulating leptin (r = -0.7, p < 0.001) and fasting insulin
(r = -0.37, p = 0.03). Circulating omentin-1 concentration increased significantly after weight loss (from 44.9 ± 9.02
to 53.41 ± 8.8 ng/ml, p < 0.001). This increase in circulating omentin after weight loss was associated with
improved insulin sensitivity (negatively associated with HOMA value and fasting insulin, r = -0.42, p = 0.02 and
r = -0.45, p = 0.01, respectively) and decreased BMI (r = -0.54, p = 0.001).
Conclusion: As previously described with adiponectin, circulating omentin-1 concentrations increase after weight
loss-induced improvement of insulin sensitivity.
Background
The communication between adipose tissue and other
biological systems is accomplished through the expres-
sion of a large number of bioactive mediators that are
collectively called ‘adipokines’ [1]. Adipokines play
important roles in the pathogenesis of insulin resistance
and associated metabolic complications such as dyslipi-
demia, hypertension, and premature heart disease [2].
Omentin-1 is a novel 34 kDa adipokine that is prefer-
entially produced by viscera la d i p o s et i s s u ec o m p a r e d
with subcutaneous adipose tissue [3,4]. Omentin-1 was
also identified in human epicardial fat [5]. In vitro
experiments revealed that treatment with recombinant
omentin-1 enhanced insulin-stimulated glucose uptake
in human subcutaneous and omental adipocytes, trigger-
ing Akt signaling in both the absence and presence of
insulin [4]. Circulating omentin-1 correlated negatively
with BMI, leptin, waist circumference, fasting insulin,
and HOMA and positively with adiponectin and HDL in
one study [6].
Weight loss is considered a key intervention to reduce
the concentrations of proinflammatory cytokines and to
increase circulating adiponectin levels [7,8]. No informa-
tion is available concerning the effects of weight loss on
circulating omentin-1 concentrations. Thus, we aimed to
evaluate the effect of weight loss-induced improvement in
insulin sensitivity on circulating omentin-1 concentrations.
Methods
Recruitment of participants
Thirthy-five Caucasian obese volunteers (17 females, 18
males) attending the Endocrinology Department at the
University Clinic of Navarra were recruited. Patients
underwent a clinical assessment including medical his-
tory, physical examination, body composition analysis,
co-morbidity evaluation as well as nutritional interviews
performed by a multidisciplinary consultation team. All
subjects were non-smokers. Patients with signs of infec-
tion were excluded. Obese patients were not receiving
statins or antidiabetic medication. The blood samples
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pre-menopausal women.
Weight loss was achieved by prescription of a diet (in
these subjects) providing a daily energy deficit of 500-
1000 kcal/d as calculated from the determination of the
resting energy expenditure through indirect calorimetry
(Vmax29, SensorMedics Corporation, Yorba Linda, Cali-
fornia) and multiplication by 1.4 as indicated for seden-
tary individual’s to obtain the patient’s total energy
expenditure. This hypocaloric regime allows a safe and
steady weight loss of 0.5-1.0 kg/wk when followed and
supplied 30, 54 and 16% of energy requirements in the
form of fat, carbohydrates and protein, respectively. The
length of the hypocaloric diet was four months.
Body fat was estimated by air-displacement-plethys-
mography (Bod-Pod®, Life Measurements, Concord,
California, USA).
The institutional review board of the institution
approved the protocol, so we certify that all applicable
institutional regulations concerning the ethical use of
information and samples from human volunteers were
followed during this research.
Analytical methods
Plasma glucose was analyzed by an automated analyzer
(Roche/Hitachi Modular P800) as previously described
[9]. Insulin was measured by means of an enzyme-
amplified chemilumi-nescence assay (IMMULITE®, Diag-
nostic Products Corp., Los Angeles, CA, USA). To esti-
mate insulin resistance, the HOMA index was
calculated as fasting insulin concentration (μU/mL) ×
fasting glucose concentration (mmol/L)/22.5.
Total serum cholesterol was measured through the
reaction of cholesterol esterase/cholesterol oxidase/per-
oxidase, using a Hitachi 747. HDL cholesterol was quan-
tified after precipitation with polyethylene glycol at
room temperature [10]. LDL cholesterol was calculated
using the Friedewald formula. Total serum triglycerides
were measured through the reaction of glycerol/phos-
phate/oxidase and peroxidase [11].
Serum omentin-1 concentrations were measured using
manual omentin-1 (human) detection set (ELISA) (APO-
TECH® Corporation, Switzerland). Serum samples were
diluted and assayed according to the manufacturer’s
instructions. Intra- and interassay coefficients of variation
were between 5% and 10%. The detection limit of the
a s s a yi s0 . 4n g / m l( r a n g e0 . 7 8t o5 0n g / m l ) .T h ea n t i b o -
dies used in this detection Set are specific for measure-
ment of natural and recombinant human omentin-1.
Statistical methods
Descriptive results of continuous variables are expressed as
mean ± SD. Relation between variables was tested using
Spearman’s test. Paired t tests were used to for comparisons
of quantitative variables across weight loss. For a given
value of p = 0.05, the study had a 99% power to detect sig-
nificant correlations between parameters in the whole sam-
ple of subjects in a bilateral test (n = 35). The analyses were
performed using the program SPSS (version 11.0).
Results
Table 1 shows the main characteristics of the subjects
included in this study and the correlations between
Table 1 Subjects’ characteristics and linear correlation analyses between circulating baseline omentin-1 concentrations
and baseline parameters in all subjects
All subjects (n = 35)
Baseline After weight loss p r* p*
Age (years) 42.4 ± 15.2 0.23 0.2
Body Mass Index (kg/m
2) 33.3 ± 4.2 28.9 ± 4.4 <0.001 -0.58 <0.001
Body weight (kg) 95.4 ± 17.5 82.4 ± 14.7 <0.001 -0.35 0.045
Fat mass (%) 41.8 ± 8.2 33.9 ± 9.9 <0.001 -0.67 <0.001
Waist (cm) 106.4 ± 11.4 96.4 ± 11.7 <0.001 -0.15 0.4
Hip (cm) 112.8 ± 10.3 104.4 ± 9.4 <0.001 -0.58 <0.001
Waist to hip ratio 0.95 ± 0.08 0.92 ± 0.07 <0.001 0.28 0.1
Fasting glucose (mmol/l) 5.2 ± 0.5 5 ± 0.43 0.04 0.23 0.2
Fasting triglycerides (mmol/l) 1.23 ± 0.5 0.92 ± 0.36 0.001 0.17 0.3
HDL-cholesterol (mmol/l) 1.37 ± 0.3 1.28 ± 0.28 0.05 -0.08 0.7
LDL-cholesterol (mmol/l) 3.3 ± 0.8 2.7 ± 0.59 <0.001 0.28 0.1
Total cholesterol (mmol/l) 5.2 ± 0.9 4.45 ± 0.61 <0.001 0.3 0.08
Fasting insulin (mU/l) 16.1 ± 8.6 12.06 ± 6.4 0.005 -0.37 0.03
HOMA value 3.6 ± 2.04 2.6 ± 1.4 0.009 -0.3 0.08
Circulating leptin (ng/ml) 35.7 ± 22.2 13.2 ± 18.2 <0.001 -0.7 <0.001
Circulating omentin-1 (ng/ml) 44.9 ± 9.02 53.4 ± 8.8 <0.001
*Correlation between circulating baseline omentin concentrations and baseline parameters.
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line study variables.
Baseline and post-weight loss omentin-1 concentra-
tions were significantly higher in men than women (48.1
±8 . 3vs. 40.3 ± 8.6 ng/ml in baseline serum, p = 0.009
and 56.4 ± 8.7 vs. 49.5 ± 8.03 ng/ml in post-weight loss
serum, p = 0.01). Baseline circulating omentin-1 concen-
trations correlated negatively with BMI (r = -0.67, p =
0.002), body weight (r = -0.57, p = 0.01), fat mass (r =
-0.48, p = 0.04), waist circumference (r = -0.47, p =
0.045), hip circumference (r = -0.52, p = 0.03) and circu-
lating leptin (r = -0.65, p = 0.003) among men (Table 2);
and with BMI (r = -0.69, p = 0.002), body weight (r =
-0.64, p = 0.006), fat mass (r = -0.63, p = 0.007), hip cir-
cumference (r = -0.67, p = 0.003), circulating leptin (r =
-0.74, p = 0.001) and fasting insulin (r = -0.64, p =
0.005) and HOMA (r = -0.55, p = 0.02) among women
(Table 3). In a multiple linear regression analyses, BMI
(p = 0.01) and sex (p = 0.01) were two independent con-
tributors to circulating omentin variance after adjusting
by fasting insulin. When we studied the participants
according to sex, we found in both cases that BMI (p =
0.038 in men and p = 0.01 in women) was an indepen-
dent contributor to circulating omentin variance after
adjusting by fasting insulin (Table 4).
Baseline and post-weight loss leptin concentrations
were significantly higher in women than men (48.27 ±
21.1 vs. 26.04 ± 17.25 ng/ml in baseline serum, p =
0.001 and 29.57 ± 18.5 vs. 9.8 ± 10.5 ng/ml in post-
weight loss serum, p = 0.01). Baseline circulating leptin
concentrations correlated with obesity measures, BMI
(r = 0.69, p = 0.001 in men and r = 0.67, p = 0.003 in
women), waist circumference (r = 0.65, p = 0.001 in
men and r = 0.55, p = 0.01 in women), hip circumfer-
ence (r = 0.71, p < 0.001 in men and r = 0.69, p = 0.001
in women) and fat mass (r = 0.62, p = 0.006 in men,
and r = 0.67, p = 0.003 in women), fasting insulin (r =
0.53, p = 0.02 in men, and r = 0.77, p < 0.001 in
women) and HOMA (r = 0.57, p = 0.01 in men, and r =
0.72, p = 0.001 in women) and inversely with circulating
omentin (r = -0.65, p = 0.003 in men, and r = -0.74, p =
0.001 in women).
After weight loss, circulating omentin-1 concentration
increased significantly in the study subjects (Table 1).
The increase in circulating omentin concentrations was
associated with the decrease of fasting insulin (r = -0.45,
p = 0.01), HOMA index (r = -0.42, p = 0.02), BMI (r =
-0.47, p = 0.003) and circulating leptin (r = -0.4, p =
0.025) (Table 5 and Figure 1 and 2). Circulating leptin
concentration decreased significantly after weight loss in
both men and women (Table 1). The decrease in circu-
lating leptin was significantly associated with the
decrease of BMI (r = 0.67, p = 0.001), fasting insulin
(r = 0.52, p = 0.044), HOMA (r = 0.54, p = 0.04) and cir-
culating omentin (r = - 0.49, p = 0.04) in men and only
with the decrease of BMI (r = 0.5, p = 0.02) in women.
Discussion
T h em a i nf i n d i n go ft h i ss t u d yw a st h eo b s e r v e d
increase in circulating omentin-1 concentration after
weight loss and its association with the improvement in
insulin sensitivity. This finding is in agreement with the
Table 2 Subjects’ characteristics and linear correlation analyses between circulating baseline omentin-1 concentrations
and baseline parameters in men
Men (n = 18)
Baseline After weight loss P r* p*
Age (years) 41.7 ± 15.1 0.28 0.25
Body Mass Index (kg/m
2) 33.3 ± 4.23 28.9 ± 4.4 <0.001 -0.67 0.002
Body Weight (kg) 102.6 ± 14.7 88.8 ± 13.2 <0.001 -0.59 0.01
Fat mass (%) 36.2 ± 5.9 27.3 ± 7.6 <0.001 -0.48 0.04
Waist (cm) 111.2 ± 7.2 99.1 ± 8.6 <0.001 -0.47 0.045
Hip (cm) 111.4 ± 8.37 104 ± 8.9 <0.001 -0.52 0.03
Waist to hip ratio 1 ± 0.05 0.95 ± 0.05 <0.001 0.11 0.6
Fasting glucose (mmol/l) 5.3 ± 0.27 5.1 ± 0.45 0.09 0.35 0.17
Fasting triglycerides (mmol/l) 1.37 ± 0.59 0.92 ± 0.37 0.002 -0.05 0.8
HDL-cholesterol (mmol/l) 1.26 ± 0.25 1.2 ± 0.27 0.17 -0.14 0.6
LDL-cholesterol (mmol/l) 3.5 ± 0.8 2.8 ± 0.6 0.001 -0.05 0.8
Total cholesterol (mmol/l) 5.4 ± 0.9 4.4 ± 0.65 <0.001 -0.07 0.8
Fasting insulin (mU/l) 14.9 ± 6.9 9.7 ± 5.6 0.005 -0.38 0.13
HOMA value 3.5 ± 1.6 2.2 ± 1.2 0.005 -0.37 0.14
Circulating Leptin (ng/ml) 23.1 ± 11.7 13.4 ± 7.8 <0.001 -0.65 0.003
Circulating omentin-1 (ng/ml) 48.6 ± 8.3 56.4 ± 8.9 0.003
*Correlation between circulating baseline omentin concentrations and baseline parameters.
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tin-1 production in healthy subjects [12]. Thus, insulin-
downregulated omentin-1 production could be behind
the inverse relationship between circulating omentin-1
and obesity.
Circulating omentin-1 was weakly correlated with
waist in men and no association was found in women,
in contrast to the correlation with hip circumference.
We may speculate that hyperinsulinemic conditions and
peripheral adiposity may reduce omentin-1 production
in morbid obese subjects.
Circulating omentin-1 concentrations measured by
ELISA were higher in men than women, although the
increase of omentin-1 after weight loss was similar in
both groups. Using quantitative western blotting, Batista
et al. [6] found increased omentin-1 concentration in
women (N = 21) compared with men (N = 18) in
genetically homogeneous population of Old order Amish.
Even though these authors concluded that more studies
were required to address this apparently divergent regu-
lation of omentin-1 between men and women. Many adi-
pokines have been found to exhibit a sexual dimorphism.
Both leptin and adiponectin are increased in serum of
women compared with men. We corroborated that in
women leptin concentration is higher than in men and
the relationship between circulating leptin and obesity,
decreasing significantly serum leptin concentration after
weight loss [13]. The strong relationship between base-
line circulating leptin and omentin-1 in men and women
was other evidence about the closed association between
omentin-1 and adiposity measures. This observation has
been explained on the basis of different fat amounts and
the influences of sex hormones. Plasma RBP4 concentra-
tions, however, exhibit an opposite pattern [14].
We compared metabolic baseline parameters between
men and women, and we found that in women fat mass
and circulating leptin were significantly higher than in
men (47.6 ± 5.7 vs. 36.2 ± 5.9%, p < 0.0001 and 48.2 ±
21.1 vs. 26.1 ± 17.2 ng/ml, p = 0.001, respectively). The
increased association among fat mass, circulating leptin
and baseline circulating omentin-1 may explain the sex
differences in omentin-1 concentration in this study.
Supporting these findings, Tan et al reported that
omental adipose tissue omentin-1 mRNA expression
and protein concentrations were negatively associated
with circulating 17b-estradiol [12].
The associations of omentin-1 with metabolic vari-
ables (6, 12, current report) were similar to those
Table 3 Subjects’ characteristics and linear correlation analyses between circulating baseline omentin-1 concentrations
and baseline parameters in women
Women (n = 17)
Baseline After weight loss P r* p*
Age (years) 43.3 ± 15.6 0.2 0.4
Body Mass Index (kg/m
2) 33.8 ± 6.45 29.2 ± 5.1 <0.001 -0.69 0.002
Body Weight (kg) 87.7 ± 17.4 75.6 ± 13.4 <0.001 -0.64 0.006
Fat mass (%) 47.6 ± 5.7 40.8 ± 6.8 <0.001 -0.63 0.007
Waist (cm) 101.5 ± 12.9 93.6 ± 14.06 <0.001 -0.44 0.08
Hip (cm) 114.2 ± 12.2 104.8 ± 10.2 <0.001 -0.67 0.003
Waist to hip ratio 0.88 ± 0.07 0.89 ± 0.08 <0.001 0.13 0.6
Fasting glucose (mmol/l) 5.04 ± 0.6 5.01 ± 0.38 0.047 -0.07 0.8
Fasting triglycerides (mmol/l) 1.06 ± 0.45 0.92 ± 0.36 0.001 0.1 0.7
HDL-cholesterol (mmol/l) 1.5 ± 0.35 1.37 ± 0.27 0.47 0.21 0.4
LDL-cholesterol (mmol/l) 3.1 ± 0.86 2.7 ± 0.6 0.001 0.35 0.2
Total cholesterol (mmol/l) 5.06 ± 0.97 4.5 ± 0.57 <0.001 0.43 0.09
Fasting insulin (mU/l) 12.03 ± 9.6 9.6 ± 7.4 0.05 -0.64 0.005
HOMA value 2.54 ± 2.2 2 ± 1.6 0.05 -0.55 0.02
Circulating Leptin (ng/ml) 32.5 ± 7.8 12.8 ± 3.8 <0.001 -0.74 0.001
Circulating omentin-1 (ng/ml) 41.1 ± 8.3 50.2 ± 7.6 0.001
*Correlation between circulating baseline omentin concentrations and baseline parameters.
Table 4 Multiple linear regression analyses with baseline
circulating omentin-1 as dependent variable before
weight loss
All subjects Men Women
Beta P Beta p Beta p
Sex -2.76 0.01 ——
Body Mass Index (kg/m
2) -2.74 0.01 -2.3 0.038 -2.9 0.01
Fasting insulin (mU/l) -0.27 0.8 0.09 0.9 -0.71 0.5
Adjusted R Square 0.39 0.28 0.36
Beta is the standardized regression coefficient, which allows evaluating the
relative significance of the each independent variable in multiple linear
regression analyses.
Adjusted R square express the percentage of the variance explained by the
independent variables in the different models (i.e., 0.50 is 50%).
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sensitizing activities.
The weak correlation of the change of omentin-1 vs.
the change of HOMA (IR) and BMI in each could be
caused by the small number of subjects of this study.
The lack of correlation of thec h a n g eo fo m e n t i n - 1v s .
the change in other variables could be explained because
the decrease of BMI was the main independent contri-
butors to circulating omentin-1 variation.
In conclusion, these preliminary findings showed
that the increase of omentin-1 concentration run in
parallel with the increase of insulin sensitivity after
weight loss.
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